AMSTERDAM, May 23, 2024 /PRNewswire/ The race to create replacement antibiotics and antifungals to combat superbugs is falling dangerously short, putting people across the world at risk.
Report assessed the efforts of major generic and biosimilar medicine manufacturers like Hikma, Teva Viatris, Cipla, and Sun Pharma in expanding access to their essential products in low- and middle-income countries
Major generic, biosimilar makers need to step up to improve access to their products in LMICs, reveals new report financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Generic companies need to improve access strategies in LMICs, says report thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.